Global Infectious Diseases Therapeutics Market - Influenza, RSV, Chlamydia, and Gonorrhoea
This research service focuses on antibiotic/antibacterial therapeutics for the treatment of infection by blood-borne (sexually transmitted) bacteria, which include Chlamydia trachomatis and Neisseria gonorrhoea as well as antiviral therapeutics for infections by vector-borne pathogens such as the influenza virus and the human respiratory syncytial virus (RSV).This research service comprises of a product and pipeline assessment for marketed and investigational products and combination regimens for the treatment of Chlamydia trachomatis, Neisseria gonorrhoeae, Influenza and RSV infections. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines, results, and epidemiology.
Ribavirin, the only approved antiviral directed at the human respiratory syncytial virus (RSV), is modestly effective. Variable response, development of resistance and viral breakthrough, along with poor tolerability and suboptimal dosing regimens, however, do not support the regular use of ribavirin.
Successful commercialisation of next-generation antibodies and the launch of cheaper biosimilar versions of Synagis are likely to result in improved immunoprophylactic therapy for RSV.
Clinical trials investigating the development of vaccines for the prevention of RSV are ongoing. Market participants strive to overcome challenges associated with incomplete immune response in very naive infants, and strain variability.
Influenza Antivirals and Vaccines
Antivirals, particularly second and third-generation neuraminidase inhibitors, are quite effective in the treatment of influenza. However, the development of resistance to antivirals remains a key challenge.
Egg-based vaccines, for the prevention of both seasonal and pandemic influenza, are currently in use.
The imminent arrival of novel innovative vaccine technologies, in terms of adjuvants, carriers, and drug delivery mechanisms, has resulted in significant sophistication levels in egg-based vaccines for the prevention of seasonal and pandemic influenza.
Nevertheless, several newer classes of antivirals, cell-based vaccines, and non-invasive drug delivery systems are currently being investigated to improve efficacy and patient compliance.
Electronic Access - Single User Fulfilled By Publisher
Electronic Access - Global Site License Fulfilled By Publisher